EA039000B1 - Композиция с противовирусным эффектом - Google Patents

Композиция с противовирусным эффектом Download PDF

Info

Publication number: EA039000B1
Authority: EA; Eurasian Patent Office
Prior art keywords: pharmaceutical composition; viral infection; benzocaine; benzalkonium chloride; tyrothricin
Prior art date: 2015-09-17

Application number

EA201890653A

Other languages

English (en)

Russian (ru)

Other versions

EA201890653A1 (ru

Inventor

Рихард Аммер

Original Assignee

Медице Арцнаймиттель Пюттер Гмбх Унд Ко. Кг.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-17

Filing date

2016-09-16

Publication date

2021-11-19

2016-09-16 Application filed by Медице Арцнаймиттель Пюттер Гмбх Унд Ко. Кг. filed Critical Медице Арцнаймиттель Пюттер Гмбх Унд Ко. Кг.

2018-08-31 Publication of EA201890653A1 publication Critical patent/EA201890653A1/ru

2021-11-19 Publication of EA039000B1 publication Critical patent/EA039000B1/ru

Links

230000000840 anti-viral effect Effects 0.000 title claims abstract description 26
239000000203 mixture Substances 0.000 title claims description 10
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims abstract description 35
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 17
229960005274 benzocaine Drugs 0.000 claims abstract description 17
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 17
230000009385 viral infection Effects 0.000 claims abstract description 14
208000036142 Viral infection Diseases 0.000 claims abstract description 13
238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
241000700605 Viruses Species 0.000 claims description 18
241000711920 Human orthopneumovirus Species 0.000 claims description 16
108010021006 Tyrothricin Proteins 0.000 claims description 16
229960003281 tyrothricin Drugs 0.000 claims description 16
GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 claims description 15
201000007100 Pharyngitis Diseases 0.000 claims description 12
206010068319 Oropharyngeal pain Diseases 0.000 claims description 5
241000430519 Human rhinovirus sp. Species 0.000 claims description 3
208000037797 influenza A Diseases 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
241000709661 Enterovirus Species 0.000 claims description 2
241000711902 Pneumovirus Species 0.000 claims description 2
241000712461 unidentified influenza virus Species 0.000 claims description 2
NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 abstract description 2
239000012895 dilution Substances 0.000 description 17
238000010790 dilution Methods 0.000 description 17
239000004480 active ingredient Substances 0.000 description 14
108010008918 benzocaine drug combination benzalkonium chloride tyrothricin Proteins 0.000 description 13
230000000694 effects Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
239000003826 tablet Substances 0.000 description 8
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 7
230000035899 viability Effects 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
239000013543 active substance Substances 0.000 description 6
229960000329 ribavirin Drugs 0.000 description 6
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 6
230000002195 synergetic effect Effects 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000013459 approach Methods 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000012085 test solution Substances 0.000 description 4
208000016150 acute pharyngitis Diseases 0.000 description 3
238000007792 addition Methods 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
244000309457 enveloped RNA virus Species 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
108010026389 Gramicidin Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
238000002636 symptomatic treatment Methods 0.000 description 2
229920000936 Agarose Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000193741 Aneurinibacillus aneurinilyticus Species 0.000 description 1
241000193764 Brevibacillus brevis Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010013789 Dry throat Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010034839 Pharyngitis streptococcal Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003212 astringent agent Substances 0.000 description 1
229940061587 calcium behenate Drugs 0.000 description 1
SMBKCSPGKDEPFO-UHFFFAOYSA-L calcium;docosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCCCC([O-])=O SMBKCSPGKDEPFO-UHFFFAOYSA-L 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229950008138 carmellose Drugs 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000249 desinfective effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
231100000284 endotoxic Toxicity 0.000 description 1
230000002346 endotoxic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
-1 fatty acid sucrose esters Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229960004905 gramicidin Drugs 0.000 description 1
ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010998 test method Methods 0.000 description 1
244000000009 viral human pathogen Species 0.000 description 1
229940100050 virazole Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001043 yellow dye Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EA201890653A 2015-09-17 2016-09-16 Композиция с противовирусным эффектом EA039000B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP15185764		2015-09-17
PCT/EP2016/071944 WO2017046312A1 (de)	2015-09-17	2016-09-16	Zusammensetzung mit antiviralem effekt

Publications (2)

Publication Number	Publication Date
EA201890653A1 EA201890653A1 (ru)	2018-08-31
EA039000B1 true EA039000B1 (ru)	2021-11-19

Family

ID=54151132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA201890653A EA039000B1 (ru)	2015-09-17	2016-09-16	Композиция с противовирусным эффектом

Country Status (6)

Country	Link
EP (1)	EP3349741A1 (es)
AR (1)	AR106057A1 (es)
DE (1)	DE202016008745U1 (es)
EA (1)	EA039000B1 (es)
UA (1)	UA123054C2 (es)
WO (1)	WO2017046312A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU101724B1 (de) *	2020-04-02	2021-10-04	Inflamed Pharma Gmbh	Wirkstoffe zur medizinischen Verwendung
WO2021198504A1 (de) *	2020-04-02	2021-10-07	Inflamed Pharma Gmbh	Wirkstoffe zur medizinischen verwendung
EP4091608B1 (en) *	2021-05-21	2024-04-17	Medice Arzneimittel Pütter GmbH & Co. KG	Composition with antiviral effect
EP4275681A1 (de) *	2022-05-10	2023-11-15	inflamed pharma GmbH	Wirkstoffe zur medizinischen verwendung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19823319A1 (de) *	1998-05-26	1999-12-02	Karl Engelhard, Fabrik Pharm.- Praeparate Gmbh & Co. Kg	Topisch anwendbares Arzneimittel zur Behandlung von Virusinfektionen
DE19823318A1 (de) *	1998-05-26	1999-12-02	Karl Engelhard, Fabrik Pharm.- Praeparate Gmbh & Co. Kg	Verwendung eines Arzneimittels mit einem Gehalt an Tyrothricin zur Behandlung von Virusinfektionen

2016
- 2016-09-16 UA UAA201803866A patent/UA123054C2/uk unknown
- 2016-09-16 WO PCT/EP2016/071944 patent/WO2017046312A1/de not_active Ceased
- 2016-09-16 EA EA201890653A patent/EA039000B1/ru unknown
- 2016-09-16 AR ARP160102836A patent/AR106057A1/es unknown
- 2016-09-16 DE DE202016008745.3U patent/DE202016008745U1/de active Active
- 2016-09-16 EP EP16767247.6A patent/EP3349741A1/de not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19823319A1 (de) *	1998-05-26	1999-12-02	Karl Engelhard, Fabrik Pharm.- Praeparate Gmbh & Co. Kg	Topisch anwendbares Arzneimittel zur Behandlung von Virusinfektionen
DE19823318A1 (de) *	1998-05-26	1999-12-02	Karl Engelhard, Fabrik Pharm.- Praeparate Gmbh & Co. Kg	Verwendung eines Arzneimittels mit einem Gehalt an Tyrothricin zur Behandlung von Virusinfektionen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARTMANN, D. ET AL: "Protective test with tyrothricin on herpes simplex virus infected mice", ARZNEIMITTEL-FORSCHUNG DRUG RESEARCH, ECD EDITTIO CANTOR VERLAG , AULENDORF, DE, vol. 29., no. 01., 1 January 1979 (1979-01-01), DE , pages 50 - 54., XP002121350, ISSN: 0004-4172 *
Michael Schmidbauer: "Pharmazeutische Zeitung online: In-vitro-Untersuchung:Dorithricin wirkt antiviral", 16 September 2015 (2015-09-16), pages 1-4, XP055317657, Retrieved from the Internet:URL:http://www.pharmazeutische-zeitung.de/index.php?id=59741[retrieved on 2016-11-09] the whole document *

Also Published As

Publication number	Publication date
EA201890653A1 (ru)	2018-08-31
WO2017046312A1 (de)	2017-03-23
EP3349741A1 (de)	2018-07-25
DE202016008745U1 (de)	2019-06-21
UA123054C2 (uk)	2021-02-10
AR106057A1 (es)	2017-12-06

Publication	Publication Date	Title
KR100824075B1 (ko)	2008-04-22	일반 감기, 알레르기성 비염 및 호흡기에 관련된 감염 증상의 치료 방법
ES2676168T3 (es)	2018-07-17	Procedimientos para tratar enfermedades gastrointestinales
US12171733B2 (en)	2024-12-24	Bactericidal and virucidal pharmaceutical composition
EA039000B1 (ru)	2021-11-19	Композиция с противовирусным эффектом
CN103189065A (zh)	2013-07-03	用于治疗上呼吸道病症的制剂
BRPI0610125A2 (pt)	2012-09-25	composição farmacêutica, kit e utilização de uma composição
CN115919830B (zh)	2025-09-26	尼泊金丁酯在增效多黏菌素类药物抗菌活性中的应用
CN114469930A (zh)	2022-05-13	马兜铃酸IVa在制备抗组胺或治疗肺炎药物中的应用
RU2657575C2 (ru)	2018-06-14	Противовирусная эффективная фармацевтическая композиция
CN107320466A (zh)	2017-11-07	厚朴酚在制备ndm‑1酶抑制剂中的医用用途
AU2022261987B2 (en)	2025-09-04	Compositions and methods for treatment of conditions using fractionated honey
CN105943540B (zh)	2019-11-19	一种西米杜鹃醇的用途
CN116617361A (zh)	2023-08-22	百里香酚在制备mcr-1酶抑制剂中的应用
RU2773949C1 (ru)	2022-06-14	Лекарственный препарат для симптоматического лечения при простудных, острых респираторных и/или других инфекционно-воспалительных заболеваниях горла
CN114712355A (zh)	2022-07-08	Rhps4在制备抑制人类病原菌药物中的应用及其药物
CN106265684A (zh)	2017-01-04	乙酰羽扇豆醇酯的应用
EP4091608B1 (en)	2024-04-17	Composition with antiviral effect
EA049050B1 (ru)	2025-02-19	Композиция с противовирусным эффектом
CN101879197B (zh)	2012-05-23	山香圆叶乙醇回流提取物及其制备方法和用途
CN1687033A (zh)	2005-10-26	一种抗呼吸道病毒的药物及用途
US20070060604A1 (en)	2007-03-15	Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment
IT202000025963A1 (it)	2022-05-02	“composizione per la prevenzione e il trattamento di affezioni dell’apparato respiratorio”
CN101073569A (zh)	2007-11-21	一种抗呼吸道病毒的药物及用途
CN1682731A (zh)	2005-10-19	具有抗感染和镇痛作用的药物
Litak	2005	Should You Put Some Zinc In That Stuffy Nose?